Company: MYSEW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001013762-25-004290
Chunk: 644

Company: Myseum, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 644
---
the “Pre-Funded Warrants”). The public offering price for each share of Common Stock was $1.85 for aggregate
gross proceeds of $708,498, and public offering price for the Pre-Funded Warrants was $1.8499 for each Pre-Funded Warrant for aggregate
gross proceeds of $1,091,441. In connection with this Offering, the Company raised aggregate gross proceeds of $1,799,939 and received
net proceeds of $1,420,773, net of Underwriters discounts and offering costs of $279,166 and legal fees of $100,000.

The per share exercise price for the Pre-Funded
Warrants was $0.0001 and the Pre-Funded Warrants were exercisable immediately. The Underwriters immediately exercised the 590,000 Pre-Funded
Warrants and the Underwriters received 589,981 shares of Common Stock since the exercise was cashless. The Pre-Funded Warrants are not
and will not be listed for trading on any national securities exchange or other nationally recognized trading system.

F-19

DATCHAT, INC. AND SUBSIDIARIES AND CONSOLIDATED ENTITIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2024 and 2023

The Company is using the net proceeds from the
Offering for general corporate purposes, for sales and marketing and for research and development.

The Underwriting Agreement contained customary
representations, warranties and covenants made by the Company. It also provided for customary indemnification by each of the Company and
the Underwriters, severally and not jointly, for losses or damages arising out of or in connection with the Offering, including for liabilities
under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. In addition, pursuant to the
terms of the Underwriting Agreement, each of the Company’s directors and executive officers entered into “lock-up” agreements
with the Representative that generally prohibit, without the prior written consent of the Representative and subject to certain exceptions,
the sale, transfer or other disposition of securities of the Company until July 17, 2024. Further, pursuant to the terms of the Underwriting
Agreement, the Company agreed for a period of 180-days from the closing date, subject to certain exceptions, not to issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of capital stock of the